Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Shin KH et al. | Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. | 2013 | Clin. Pharmacol. Ther. | pmid:23784264 |
Tomalik-Scharte D et al. | Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? | 2009 | Clin. Pharmacol. Ther. | pmid:19458613 |
Oh J et al. | Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel dipeptidyl peptidase-4 inhibitor, evogliptin (DA-1229). | 2017 | Diabetes Obes Metab | pmid:27761990 |
Björkhem-Bergman L et al. | Serum levels of 25-hydroxyvitamin D and the CYP3A biomarker 4β-hydroxycholesterol in a high-dose vitamin D supplementation study. | 2013 | Drug Metab. Dispos. | pmid:23386704 |
Peters J et al. | Oral absorption of clarithromycin is nearly abolished by chronic comedication of rifampicin in foals. | 2011 | Drug Metab. Dispos. | pmid:21690264 |
Suzuki Y et al. | Association of plasma concentration of 4β-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients. | 2014 | Drug Metab. Dispos. | pmid:24135442 |
Li K et al. | 4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys. | 2014 | Drug Metab. Dispos. | pmid:24595680 |
Björkhem-Bergman L et al. | Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin. | 2013 | Drug Metab. Dispos. | pmid:23674608 |
Ishida T et al. | Relationship between the plasma fentanyl and serum 4β-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain. | 2016 | Drug Metab. Pharmacokinet. | pmid:27236640 |
Naito T et al. | CYP3A activity based on plasma 4β-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine. | 2015 | Drug Metab. Pharmacokinet. | pmid:26654672 |